Company: MDCXW
Filing Date: 2025-09-11
Form Type: DRS
Source: 0001062993-25-015568
Chunk: 230

Company: Medicus Pharma Ltd.
Filing Date: 2025-09-11
Form: DRS
Chunk 230
---
, if any, under the SEPA, the common shares owned by our existing shareholders would represent a smaller percentage of our total outstanding common shares after any such issuance.

The following table sets forth the number of common shares to be issued to the Selling Shareholder under the SEPA at varying purchase prices:

| Assumed Average 
 Purchase Price  
 Per Share       |   Number of Registered 
 Shares to be Issued if 
       Full Purchase(1) | Percentage of Outstanding  
 Shares After Giving Effect 
 to the Issuance to the     
 Selling Shareholder(2)     |       Gross Proceeds from the 
 Sale of Shares to the Selling 
         Shareholder Under the 
                          SEPA |
| $1.00           |              9,390,000 | 44.3%                      |                    $9,390,000 |
| $1.50           |              9,390,000 | 44.3%                      |                   $14,085,000 |
| $2.00           |              7,500,000 | 38.8%                      |                   $15,000,000 |
| $2.80(3)        |              5,357,143 | 31.2%                      |                   $15,000,000 |
| $3.00           |              5,000,000 | 29.7%                      |                   $15,000,000 |
| $4.00           |              3,750,000 | 24.1%                      |                   $15,000,000 |
| $5.00           |              3,000,000 | 20.2%                      |                   $15,000,000 |

(1)Does not include 105,840 Commitment Shares that we issued to the Selling Shareholder as consideration for its commitment to purchase common shares under the SEPA. The number of common shares offered by this prospectus, even when combined with the 1,890,000 previously issued to the Selling Shareholder as of the date of this prospectus, for sale by the Selling Shareholder pursuant to the Prior Registration Statement, may not cover all the shares we ultimately sell to the Selling Shareholder under the SEPA, depending on the purchase price per share. We have included in this column both those shares being offered for resale by the Selling Shareholder under this prospectus (excluding the 105,840 Commitment Shares) and those 1,890,000 common shares previously issued